Oramed Pharmaceuticals (ORMP) Non-Current Assets (2011 - 2026)

Oramed Pharmaceuticals' Non-Current Assets history runs 16 years deep, the most recent figure standing at $200.7 million for Q1 2026.

• Quarterly Non-Current Assets rose 1149.44% year-over-year to $200.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.7 million (up 1149.44% YoY) and the FY2025 annual result came in at $97.6 million, up 709.43% from the prior year.
• Non-Current Assets was $200.7 million for Q1 2026 at Oramed Pharmaceuticals, up from $97.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $200.7 million in Q1 2026 and bottomed at $4.3 million in Q3 2022.
• A 5-year average of $43.6 million and a median of $27.4 million in 2022 frame the typical range for Non-Current Assets.
• Peak annual rise in Non-Current Assets reached 1193.97% in 2023, while the deepest fall reached 83.87% in 2023.
• Oramed Pharmaceuticals' Non-Current Assets stood at $4.5 million in 2022, then jumped by 1178.78% to $58.0 million in 2023, then slumped by 79.2% to $12.1 million in 2024, then surged by 709.43% to $97.6 million in 2025, then surged by 105.65% to $200.7 million in 2026.
• Business Quant data shows ORMP's Non-Current Assets at $200.7 million in Q1 2026, $97.6 million in Q4 2025, and $84.4 million in Q3 2025.